Pictured: Eli Lilly's biotechnology center in San Diego, California/iStock, JHVEPhoto

图为：加利福尼亚州圣地亚哥的礼来生物技术中心/JHVEPhoto伊斯托克

Eli Lilly is enlisting the help of Amazon Pharmacy to fill prescriptions of its blockbuster weight-loss treatment Zepbound (tirzepatide), according to several media reports on Wednesday.

据周三多家媒体报道，礼来公司正在寻求亚马逊药房的帮助，以满足其畅销减肥药Zepbound（tirzepatide）的处方需求。

Under the arrangement, Amazon Pharmacy will deliver prescriptions of Zepbound—as well as Lilly’s migraine and diabetes medicines—to patients who ordered them via the pharma’s end-to-end digital health portal LillyDirect. Amazon can deliver orders out within two days for certain patients, according to CNBC..

根据协议，亚马逊药店将向通过药店端到端数字健康门户网站LillyDirect订购Zepbound以及礼来偏头痛和糖尿病药物的患者提供处方。据CNBC报道，亚马逊可以在两天内为某些患者下订单。。

Amazon Pharmacy is LillyDirect’s second online dispensing partner, following the digital health start-up Truepill. The bulk of online orders will be split between the two distributors, with final fulfillment carried out according to the customers’ insurance provider and other personal details.

亚马逊药房是LillyDirect继数字健康初创公司Truepill之后的第二个在线配药合作伙伴。大部分在线订单将在两个分销商之间进行分配，最终履行将根据客户的保险提供商和其他个人信息进行。

CNBC reported that Lilly expects Amazon and Truepill to have similar processing times.

CNBC报道，礼来预计亚马逊和Truepill的处理时间相似。

Amazon makes for a good distribution partner for Lilly because of its “experience in developing tech-enabled solutions,” Frank Cunningham, vice president of global value and access at Lilly, told Endpoints News. “We liked their commitment to patient safety, simplifying the pharmacy experience and great customer service.”.

礼来负责全球价值和访问的副总裁弗兰克·坎宁安（FrankCunningham）告诉Endpoints News，亚马逊凭借其“开发技术支持解决方案的经验”成为礼来的良好分销合作伙伴。“我们喜欢他们对患者安全的承诺，简化了药房体验和出色的客户服务。”。

Lilly is also mulling a partnership with a retail pharmacy to allow for pick-up options for orders placed on LillyDirect, Cunningham told Reuters.

坎宁安（Cunningham）告诉路透社（Reuters），礼来（Lilly）也在考虑与一家零售药店合作，为LillyDirect上的订单提供提货选择。

Launched in January 2024, LillyDirect is an online platform that caters to U.S. patients with obesity, migraine and diabetes. LillyDirect offers customers a “digital pharmacy” for some of the company’s medicines and is designed to provide consistent access to prescription access, along with the convenience of home delivery..

LillyDirect于2024年1月推出，是一个面向美国肥胖、偏头痛和糖尿病患者的在线平台。LillyDirect为客户提供公司某些药物的“数字药房”，旨在为客户提供一致的处方访问权限，同时方便家庭递送。。

LillyDirect’s online pharmacy solutions are also meant to help patients access the company’s affordability and savings opportunities, according to Lilly.

LillyDirect的在线药房解决方案也旨在帮助患者获得公司的负担能力和储蓄机会，据Lilly称。

The digital health platform also provides access to independent telehealth providers to complement patients’ existing care teams, as well as educational information. Lilly will continue to expand LillyDirect and future updates may include new products, partners and other services, the company said.

数字健康平台还提供独立远程保健提供者的访问，以补充患者现有的护理团队以及教育信息。礼来公司表示，礼来将继续扩大LillyDirect，未来的更新可能包括新产品、合作伙伴和其他服务。

Lilly’s digital push comes as the pharma continues to ride the sky-high demand for obesity therapies. Currently, Lilly and Novo Nordisk—which owns the semaglutide products Wegovy and Ozempic—have a virtual duopoly on the obesity space and are poised to capture the vast majority of the potential $200 billion market in the coming years..

礼来的数字推广之际，这家制药公司继续满足对肥胖治疗的极高需求。目前，拥有semaglutide产品Wegovy和Ozempic的礼来和诺和诺德在肥胖症领域实际上处于双寡头垄断地位，并有望在未来几年占据2000亿美元潜在市场的绝大多数。。

Several companies are also eyeing a slice of the massive weight-loss market including Regeneron, which is advancing a pair of muscle-preserving antibodies designed to improve the quality of weight loss when used in conjunction with the current GLP-1 receptor agonists.

包括Regeneron在内的几家公司也在关注大规模减肥市场的一部分，Regeneron正在开发一对肌肉保护抗体，旨在与当前的GLP-1受体激动剂联合使用时改善减肥质量。

Also in the race is Amgen, which has a Phase I candidate called MariTide that last month showed longer-lasting effects than current therapies on the market. Boehringer Ingelheim is also looking to challenge Lilly and Novo with its glucagon/GLP-1 receptor dual agonist survodutide, for which it launched three Phase III trials in August 2023..

安进（Amgen）也参加了这场比赛，它有一个名为马里蒂德（MariTide）的I期候选药物，上个月显示出比目前市场上的疗法更持久的效果。勃林格殷格翰公司也在寻求用其胰高血糖素/GLP-1受体双重激动剂舒沃杜肽挑战礼来和诺沃，为此它于2023年8月启动了三期III期试验。。

Tristan Manalac is an independent science writer based in Metro Manila, Philippines. Reach out to him on LinkedIn or email him at tristan@tristanmanalac.com or tristan.manalac@biospace.com.

特里斯坦·马纳拉克（TristanManalac）是一位独立的科学作家，总部位于菲律宾马尼拉。在LinkedIn上联系他，或发电子邮件给他tristan@tristanmanalac.com或tristan.manalac@biospace.com.